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Abstract
Background: The burden of breast cancer in Asia is escalating. We evaluated the impact of ethnicity on survival after breast
cancer in the multi-ethnic region of South East Asia.
Methodology/Principal Findings: Using the Singapore-Malaysia hospital-based breast cancer registry, we analyzed the
association between ethnicity and mortality following breast cancer in 5,264 patients diagnosed between 1990 and 2007
(Chinese: 71.6%, Malay: 18.4%, Indian: 10.0%). We compared survival rates between ethnic groups and calculated adjusted
hazard ratios (HR) to estimate the independent effect of ethnicity on survival. Malays (n = 968) presented at a significantly
younger age, with larger tumors, and at later stages than the Chinese and Indians. Malays were also more likely to have
axillary lymph node metastasis at similar tumor sizes and to have hormone receptor negative and poorly differentiated
tumors. Five year overall survival was highest in the Chinese women (75.8%; 95%CI: 74.4%–77.3%) followed by Indians
(68.0%; 95%CI: 63.8%–72.2%), and Malays (58.5%; 95%CI: 55.2%–61.7%). Compared to the Chinese, Malay ethnicity was
associated with significantly higher risk of all-cause mortality (HR: 1.34; 95%CI: 1.19–1.51), independent of age, stage, tumor
characteristics and treatment. Indian ethnicity was not significantly associated with risk of mortality after breast cancer
compared to the Chinese (HR: 1.14; 95%CI: 0.98–1.34).
Conclusion: In South East Asia, Malay ethnicity is independently associated with poorer survival after breast cancer.
Research into underlying reasons, potentially including variations in tumor biology, psychosocial factors, treatment
responsiveness and lifestyle after diagnosis, is warranted.
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Introduction
In contrast to the West, where breast cancer incidence rates
have plateaued or even decreased [1,2], the incidence of breast
cancer is rapidly escalating in Asia. In China and India, breast
cancer rates have increased by up to 30% over the last 10 years,
while in Japan, Korea and Singapore, incidence rates have
doubled or even tripled in the past few decades [3]. Studies in
Western settings have implicated ethnicity as a predictor of
survival following breast cancer [4]. However, the impact of
ethnicity on survival after breast cancer in Asian settings has
hardly been studied.
South East Asia, with distinct genetic, cultural and lifestyle
diversity was recently highlighted as an emerging focus for global
health [5]. In Malaysia and Singapore, multiethnic nations
comprising 3 major ethnic groups namely Malays, Chinese and
Indians [6,7], age-standardized incidence rates of breast cancer
differ substantially. The rate is highest among the Chinese
followed by the Indians and the Malays [6,7]. Whilst Malay
women have the lowest incidence of breast cancer, there is also
some evidence of poorer prognosis compared to their Chinese and
Indian counterparts [8]. It remains unclear whether stage at
diagnosis, tumor characteristics, or treatment explains the survival
disparities.
Using a large multicenter hospital-based cohort of breast cancer
patients from Malaysia and Singapore, we investigated the impact
of ethnicity on survival after breast cancer, and possible
mechanisms to explain the survival disparities.
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Methods
Ethics statement
The NUS Breast Cancer Registry has received approval from
the NUS Institutional Review Board (NUS-IRB). The University
Malaya Breast Cancer Registry was approved by the University
Malaya’s Ethical Committee. This study was approved by the
respective ethical committees in both institutions. As the study
relies on non-identifiable registry-based data, the need to obtain
informed consent was waived.
Participants
We used data from the Singapore-Malaysia Breast Cancer
Registry which currently encompasses 5,769 women. This multi-
institutional breast cancer registry is a merger between the
National University Hospital (NUH) Breast Cancer Registry,
and the University Malaya Medical Center (UMMC) Breast
Cancer Registry [9]. The NUH is a tertiary university hospital in
the city state of Singapore. Its breast cancer registry includes all
consecutive 2,449 women diagnosed with breast cancer between
1990 and 2007. Information has been collected retrospectively
between 1990 and 1995 and prospectively from 1995 to 2007.
UMMC is an academic tertiary hospital situated in the relatively
affluent part of Kuala Lumpur (Malaysia) and caters to a
predominantly middle class urban population. The UMMC
Breast Cancer Registry is a prospective database of 3,320
consecutive women who were newly diagnosed with breast cancer
between 1993 and 2007.
In the current study, we included all 5,264 women from the
three major ethnic groups in Malaysia and Singapore i.e. Chinese,
Malays and Indians, who were diagnosed with invasive breast
cancer. Women of other ethnic minorities (n = 198) were excluded
as were women with carcinoma in situ (n = 307).
Study variables
The determinant of interest was ethnicity (Chinese, Malay,
Indian), and the outcome was death from all causes. Data on
patient characteristics included age at diagnosis, and center of
treatment (NUH, UMMC). Patients were staged according to the
5th edition of TNM American Joint Committee on Cancer (AJCC)
system if diagnosed before January 1st 2003, and according to the
6th edition of AJCC if diagnosed after this date. Variables on
disease characteristics included pathologically determined tumor
size (available as continuous value and categorized into 0?1–
20.0 mm, 20?1–50?00 mm, .50?0 mm, unknown), pathologically
determined lymph node involvement (available as absolute
number of positive nodes and categorized into yes, no, unknown),
distant metastasis (detected by means of computed tomography of
the thorax, abdomen and pelvis, and bone scan in patients with
clinical stage III breast cancer; yes, no, unknown), estrogen
receptor (ER) status/progesterone receptor (PR) status (positive
when .10% of tumor cells stained positive during immunohisto-
chemical testing, negative, unknown), and tumor grade (Scarff-
Bloom-Richardson classification; grade 1, grade 2, grade 3,
unknown). Loco-regional treatment was classified as no loco-
regional treatment, complete loco-regional treatment (i.e. mastec-
tomy, or breast conserving surgery [BCS] followed by radiother-
apy), and incomplete treatment (i.e. BCS only, or radiotherapy
only). Administration of chemotherapy, and hormone therapy
were categorized as yes and no.
Follow-up and outcome assessment
In both centers, patients were monitored via scheduled
appointments in the specialist breast clinics. Data on mortality
were obtained from the hospitals’ medical records, as well as
through active follow-up. In addition, vital status was verified
through direct linkage with the National Registration Department
in Malaysia. In this hospital based cancer registry, information on
cause of death or cancer recurrence was not available for the
majority of patients. Follow-up time was calculated as the interval
between date of diagnosis and date of death, or date of last contact,
whichever came first.
Statistical analysis
All categorical variables were described by proportions and
compared using the Chi square test. Continuous variables were
expressed in medians and compared using the Kruskal Wallis test.
Overall survival was estimated using Kaplan-Meier analyses and
compared by log-rank test.
Cox regression analysis was performed to estimate the relative
risk for all-cause mortality expressed as hazard ratio (HR) between
women of different ethnicities. Time at entry was date of diagnosis
with breast cancer, and exit time was date of death (from all
causes), date at last contact, or Nov, 2010 (linkage with national
mortality registry in Malaysia). This model was adjusted for age at
diagnosis, center, year of diagnosis, tumor size, lymph node
involvement, metastases, estrogen and progesterone receptor
status, tumor grade, loco-regional therapy, chemotherapy, and
hormone therapy.
Within the subgroup of patients with pathologically confirmed
tumor size and lymph node status (N=3,712), we studied possible
effect modification by tumor size on the association between
ethnicity and lymph node metastasis by including the interaction
terms ‘ethnic groups multiplied by tumor size in mm’ into a logistic
regression model with lymph node involvement as the outcome.
Patients were subsequently grouped according to tumor size
,20 mm, 20 to 50 mm, and .50 mm. Within each category,
logistic regression analysis was used to determine the association
between lymph node involvement (outcome) and ethnicity
(predictor), adjusted for absolute tumor size (mm), tumor grade,
ER status and PR status.
Two-tailed p-values below 0?05 and HRs with 95%CI which
did not include 1?00 were considered as statistically significant. All
analyses were performed using SAS version 9?1 (SAS Institute Inc,
Cary, NC).
Results
Descriptive data
In this hospital based cohort of 5,264 multi-ethnic Asian women
with breast cancer, there were 3,767 Chinese (71?6%), 968 Malays
(18?4%) and 529 Indians (10?0%). Median age at diagnosis was 50
years (Table 1). Malay patients were significantly younger at
diagnosis (median = 46 years) than Chinese (51 years) and Indian
(53 years) women; p,0?001.
The median tumor diameter was higher among Malay women
(35 mm) than among Chinese (25 mm) and Indian (30 mm)
women (p,0?001). Sixteen percent of Malay women were
diagnosed with distant metastases (TNM stage IV) at presentation
compared with 9% among Chinese and 4% among Indian women
(Table 1). Chinese women were more likely than women of other
ethnicities to present with stage I breast cancer and exhibit
favorable tumor characteristics such as ER positivity (p = 0?002),
PR positivity (p,0?001) or good differentiation (p,0?001).
Among women with non-metastatic breast cancer, the Malays
were least likely to receive complete loco-regional treatment
(Table 1). Within the subgroup of women who underwent breast
surgery, a higher proportion of Malay women underwent breast
Ethnicity and Breast Cancer Survival in Asia
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conserving surgery compared to Chinese or Indian women (34?2%
vs. 23?7% vs. 25?6%, respectively; p,0?001). Overall, Malay
women were significantly more likely to receive chemotherapy
compared to women from other ethnic groups (Table 1). Among
women with estrogen receptor positive tumors, Malays were
significantly less likely to receive hormonal therapy compared to
the Chinese and Indians (79.1% vs. 87.3% vs. 90.9%; p,0.001).
Survival
After 30,882 person-years of follow-up, a total of 1,690 deaths
from all causes had occurred. Five year overall survival was highest
in the Chinese women (75?8%; 95%CI: 74?4%–77?3%) followed
by Indians (68?0%; 95%CI: 63?8%–72?2%), and Malays (58?5%;
95%CI: 55?2%–61?7%) (Figure 1). Among patients with early
breast cancer (stage I and II), the Chinese also had the highest
overall survival (88?1%; 95%CI: 86?8%–88?3%), whereas survival
was not significantly different between the Indians (80?5%;
95%CI: 76?1%–84?9%) and the Malays (77?5%; 95%CI:
73?8%–81?2%). In the more advanced stages (stage III & IV),
the survival of the Chinese and Indian patients did not differ
significantly (43?7%; 95%CI: 40?4%–47?0% and 43?3%; 95%CI:
35?5%–51?1%, respectively), whereas the Malays had significantly
lower survival (34?4%; 95%CI: 29?6%–39?2%) than the Chinese.
Following adjustment for age at diagnosis, calendar year, and
center, Malay patients with breast cancer were associated with
substantially increased risk of death as compared to their Chinese
counterparts whereas, Indian ethnicity was associated with
moderately increased risk (Table 2). These mortality risks further
Table 1. Distribution of Patient Profile, Tumor Characteristics and Treatment According to Ethnicity in 5,264 Southeast Asian
Women with Breast Cancer.
Total Chinese Malay Indian P valueb
N=5 264 N=3 767 N=968 N=529
N (%)a n (%)a n (%)a n (%)a
Median age at diagnosis, years 50 51 46 53 ,0?001
Median tumor size, mmc 30 25 35 30 ,0?001
Lymph node involvement ,0?001
Absent 2 804 (54?7) 2 106 (57?1) 429 (46?4) 269 (52?0)
Present 2 324 (45?3) 1 580 (42?9) 496 (53?6) 248 (48?0)
Unknown 136 81 43 12
Estrogen receptor status 0?004
Positive 2 436 (56?6) 1 825 (58?1) 407 (52?5) 231 (52?5)
Negative 1 892 (43?4) 1 315 (41?9) 368 (47?5) 209 (47?5)
Unknown 909 627 193 89
Progesterone receptor status 0.172
Positive 1 960 (52?4) 1 469 (53?3) 321 (50?7) 170 (48?7)
Negative 1 778 (47?6) 1 287 (46?7) 312 (49?3) 179 (51?3)
Unknown 1 526 1 011 335 180
Tumor grade 0.002
Good differentiation 466 (11?8) 375 (13?0) 57 (8?5) 34 (8?8)
Moderate differentiation 1 864 (47?4) 1 368 (47?5) 313 (46?8) 183 (47?3)
Poor differentiation 1 604 (40?8) 1 135 (39?4) 299 (44?7) 170 (43?9)
Unknown 1 330 889 299 142
Loco-regional therapyd ,0?001
Complete treatment 4 140 (90?2) 3 081 (92?7) 636 (79?8) 423 (90?2)
Incomplete treatment 206 (4?5) 135 (4?1) 50 (6?3) 21 (4?5)
None 243 (5?3) 107 (3?2) 111 (13?9) 25 (5?3)
Chemotherapy 0?001
Yes 3 116 (59?2) 2 172 (57?7) 617 (63?7) 327 (61?8)
No 2 148 (40?8) 1 595 (42?3) 351 (36?3) 202 (38?2)
Hormone therapye ,0?001
Yes 2 372 (85?6) 1 777 (86?5) 361 (79?0) 234 (89?7)
No 400 (14?4) 277 (13?5) 96 (21?0) 27 (10?3)
aColumn percentage is presented except for center where row percentage is presented.
bCompared using x2 test for categorical variables and Kruskal Wallis test for continuous variables.
cAbsolute tumor size was only available in 4 359 patients i.e. in 80.4% of the Chinese, 89.2% of Malays and 88.5% of Indians.
dOnly includes 4,589 patients with TNM stage I to stage III breast cancer. Complete treatment consists of mastectomy, or breast conserving surgery followed by
radiotherapy. Incomplete treatment includes breast conserving surgery only or radiotherapy only.
eOnly includes 2 772 patients with estrogen or progesterone receptor positive tumors.
doi:10.1371/journal.pone.0030995.t001
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attenuated when we adjusted for tumor size at presentation, which
may be regarded as a proxy of health awareness in our population;
HR for Malays versus Chinese: 1?66; 95%CI: 1?48–1?86, and HR
for Indians versus Chinese: 1?14; 95%CI: 0?98–1?33. In a full
model adjusted for socio-demographic factors, tumor character-
istics and treatment, Malay ethnicity remained independently
associated with risk of mortality following breast cancer compared
to the Chinese (HR: 1.34; 95%CI: 1.19–1.51). However, there was
no significant difference in mortality between the Chinese and
Indian breast cancer patients.
Tumor size and axillary metastases
It was found that tumor size significantly modifies the association
between Malay ethnicity and axillary lymph node involvement (p
for interaction= 0.028) but not for Indian ethnicity (p= 0.603).
Within the subgroup of tumors below 20 mm, Malay patients were
significantly more likely to have lymph node involvement compared
to the Chinese and Indian women with breast cancer (35?4% versus
23?0% versus 17?4%, respectively; p= 0?004) (Table 3). Malay
ethnicity remains significantly associated with an increased risk of
axillary lymph node metastasis compared to the Chinese after
adjustment for other tumor characteristics (adjusted OR 1?57, 95%
CI: 1?05–2?37). In tumors measuring 20–50 mm, Malay patients
were also more likely to have lymph node involvement (adjusted
OR: 1?45; 95%CI: 1?15–1?84).
Discussion
With this study, we have shown marked ethnic differences in
disease presentation, treatment patterns, and survival of breast
cancer patients in South East Asia. Women of Malay ethnicity
presented at more advanced stages of breast cancer than women
belonging to other ethnic groups. The Malays also seem to have a
more aggressive tumor biology compared to the Chinese breast
cancer patients. Furthermore, Malay ethnicity is associated with
higher risk of death following breast cancer, even after accounting
for demographic factors, tumor characteristics and treatment.
To our knowledge, this is the first large study to shed light on
the impact of ethnicity on the survival of women following breast
cancer in the Asian context. Strengths of our study include detailed
information on tumor characteristics and treatment profile which
are important prognostic determinants of survival related to breast
cancer. Nevertheless, information on HER2 status was lacking,
and we are unsure of its influence on the study findings. We also
did not have adequate information on the causes of death of
patients making it impossible to study breast cancer specific
survival. We acknowledge that ethnic differences in co-morbidity
and life expectancy may partly explain the observed ethnic
disparities in survival. Chinese women in South East Asia have the
highest life expectancy at birth (e.g. 77?1 years) whereas the Malay
(73?6 years) and Indian (72?1 years) women have a slightly lower
life expectancy [10,11]. Nevertheless, these differences in life
expectancy are unlikely to completely explain our results. The
relationship between ethnicity and breast cancer survival seems
complex and a variety of factors have been proposed to explain the
ethnic disparities in breast cancer survival [4].
Ethnic differences in socio-economic status and cultural
values
Ethnicity has often been considered a proxy for socio-economic
status [12], whereby a low socio-economic status has been linked
to late stage at diagnosis with cancer [13], unequal access to
Figure 1. Cumulative overall survival by ethnicity in 5,264 South East Asian women with breast cancer.
doi:10.1371/journal.pone.0030995.g001
Table 2. Association between Ethnicity and All-Cause
Mortality Following Diagnosis with Breast Cancer in 5,264
Southeast Asian Women.
Chinese N=3 767 Malays N=968 Indians N=529
Hazard Ratio 1.00 1?90 1?24
(95%CI)a (1?70–2?13) (1?06–1?44)
Hazard Ratio 1.00 1?45 1?15
(95%CI)b (1?29–1?63) (0?98–1?34)
Hazard Ratio 1.00 1.34 1.14
(95%CI)c (1?19–1?51) (0.98–1.34)
aEstimated from Cox regression model adjusted for age at diagnosis, center,
and year of diagnosis.
bEstimated from Cox regression model adjusted for age at diagnosis, center,
year of diagnosis, tumor size, lymph node involvement, distant metastasis,
estrogen receptor status, progesterone receptor status, and tumor grade.
cEstimated from Cox regression model adjusted for age at diagnosis, center,
year of diagnosis, tumor size, lymph node involvement, distant metastasis,
estrogen receptor status, progesterone receptor status, tumor grade, loco-
regional therapy, chemotherapy, and hormone therapy.
doi:10.1371/journal.pone.0030995.t002
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optimal treatment [14], and poorer treatment adherence [15]. In
our population, the Chinese have the highest household income
and are most likely to receive tertiary education, whereas the
Malays have the lowest income and education status, and the
Indians fall in between [16,17]. In the current study, Malay
women presented at later stages of cancer and were less likely to
receive complete loco-regional therapy and hormone therapy.
Although socioeconomic status is a strong determinant of outcome
in many chronic diseases, it is nevertheless unable to fully explain
ethnic disparities in survival [18,19].
In addition to socio-economic differences, we also see religious
differences in our three ethnic groups, whereby the Malays are
mostly Muslims, the Chinese are either Buddhists or Christians,
and the Indians are mainly Hindus [16]. As religion and culture is
intertwined, it is likely that psychosocial and cultural factors such
as folk/religious beliefs, relationships with men, perceived risk, and
beliefs in various treatments for breast cancer, may have an impact
on disease awareness, access to early detection and thus stage at
presentation of breast cancer [19]. Corroborating these, the
emerging themes from a study in Malaysian women who
presented at late stage breast cancer were cancer fatalism (i.e.
the belief that death is inevitable when cancer is present), and use
of alternative therapy [20]. Besides influencing stage at diagnosis,
the above factors may also influence treatment acceptance and
adherence [21].
Ethnic differences in tumor biology
Ethnic variations in tumor biology have been reported, whereby
certain ethnic groups are more likely to have unfavorable cancer
types such as hormone receptor negative tumors, HER2 over-
expression, basal-like breast tumors, or high grade tumors [22,23].
In our study, Malay patients had more aggressive tumors
compared to other races, as indicated by their higher risk of
axillary lymph node metastasis at similar tumor sizes. Moreover,
Malay and Indian women were more likely to have unfavorable
tumor characteristics such as hormonal negative and high grade
tumors. Adjustment for tumor related factors substantially
attenuated the excess mortality in Indian patients but did not
eliminate it completely among the Malays. As full characterization
of breast cancer by molecular subgroups was not carried out in this
study, we are unsure of its impact on our findings.
Ethnic differences in response to treatment
There may be ethnic differences in tolerability and response to
hormonal treatment and cytotoxic chemotherapy in breast cancer
[24]. For instance, the activities of the CYP P450 group of
enzymes which are responsible in metabolizing anti-hormonal
drugs seem to vary between ethnic groups, due to underlying
differences in functional polymorphisms [24]. Hence, anti-
hormonal drugs such as tamoxifen may be more effective in
certain ethnic groups. Furthermore, genotype-phenotype associa-
tions have been suggested based on studies among Chinese, Malay
and Indian patients receiving doxorubicin [25,26]. Compared to
other ethnic groups Chinese may be predisposed to higher
concentrations of doxorubicin associated with higher frequencies
of polymorphism within the SLC22A16 gene [25], or CBR3 gene
[26]. Certain anticancer therapies may therefore be more effective
in the Chinese.
Ethnic differences in lifestyle
Lifestyle factors, such as diet and body weight, are increasingly
being recognized as important prognostic factors of breast cancer
[4]. Owing to differences in religious and cultural practices,
lifestyle profiles do differ substantially between the ethnic groups in
South East Asia. In terms of diet, Malay women, for instance, are
less likely to consume alcohol, whereas the Chinese women have a
high intake of soy and consume the lowest amount of dietary fat
[27]. A study conducted in China suggested that dietary practices
such as increased soy intake are associated with decreased risk of
death and recurrence among breast cancer survivors [28].
We also see important differences in prevalence of overweight
and obesity in our three ethnic groups. Obesity is more common
in Malay and Indian women, whereas the Chinese have the lowest
body mass index [29,30]. Obesity has been linked to late stage at
Table 3. Association between ethnic groups and lymph node involvement by tumor size in 3,712 Asian women with breast
cancer.a
Ethnicity P valueb
Chinese Malay Indian
Tumor size less than 20 mm (N=937) 0.004
No nodal involvement, N (%) 568 (77?0) 84 (64?6) 57 (82?6)
Lymph node involvement, N (%) 170 (23?0) 46 (35?4) 12 (17?4)
Adjusted odds ratio for lymph node involvementc (95% confidence interval) 1.00 1?57 (1?05–2?37) 0?64 (0?33–1?24)
Tumor size 20–50 mm (N=2,228) 0.002
No nodal involvement, N (%) 865 (53?8) 160 (43?7) 125 (49?0)
Lymph node involvement, N (%) 742 (46?2) 206 (56?3) 130 (51?0)
Adjusted odds ratio for lymph node involvementc (95% confidence interval) 1.00 1?45 (1?15–1?84) 1?18 (0?89–1?55)
Tumor size more than 50 mm (N=547) 0.215
No nodal involvement, N (%) 105 (30?9) 34 (25?2) 16 (2?2)
Lymph node involvement, N (%) 235 (69?1) 101 (74?8) 56 (77?8)
Adjusted odds ratio for lymph node involvementc (95% confidence interval) 1.00 1?40 (0?88–2?23) 1?69 (0?92–3?13)
aOnly including patients with pathologically confirmed tumor size and lymph node status.
bUsing Chi Square test.
cLogistic regression model adjusted for absolute tumor size (mm), tumor grade, estrogen receptor status, and progesterone receptor status.
doi:10.1371/journal.pone.0030995.t003
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presentation of breast cancer as well as substandard diagnostic
work-up [31]. In addition, body weight and weight gain after the
diagnosis of breast cancer have also been implicated in prognosis
of breast cancer [32], which might explain some of the excess
mortality among Malay and Indian women.
Our findings highlight the problem of late presentation among
the Malays. As psychosocial and cultural factors, as well as
socioeconomic status may contribute to delayed presentation
[19,20], culturally-sensitive programs and oncology practices are
needed to improve breast health literacy in South East Asia. Such
programs should aim to encourage early detection of breast cancer
especially among the Malay women via participation in cancer
screening activities such as self-breast examination, clinical breast
examination, and mammographic screening. Further research is
needed in Asian women to investigate tumor biology, ethnic
differences in genetic variants associated with response to
anticancer therapy and impact of cultural and lifestyle determi-
nants on breast cancer survival.
In conclusion, Malay ethnicity is significantly associated with
poorer survival following the diagnosis of breast cancer. The
underlying reasons for this association are unclear but maybe
explained by variations in tumor biology, psychosocial and
cultural beliefs, susceptibility to anticancer treatment and lifestyle
after diagnosis of breast cancer.
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